AJR Am J Roentgenol
- PENG Y, Zhang X, Qiu Y, Li B, et al
Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero,
-Low, and -Positive Breast Cancer.
AJR Am J Roentgenol. 2024 Jan 24. doi: 10.2214/AJR.23.30603.
Ann Oncol
- HARVEY-JONES E, Raghunandan M, Robbez-Masson L, Magraner-Pardo L, et al
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1
and PAXIP1 mutations in PARP inhibitor resistant advanced breast cancer.
Ann Oncol. 2024 Jan 18:S0923-7534(24)00010-3. doi: 10.1016/j.annonc.2024.
Ann Surg Oncol
- CORTINA CS, Lloren JI, Rogers C, Johnson MK, et al
Does Neoadjuvant Chemotherapy in Clinical T1-T2 N0 Triple-Negative Breast Cancer
Increase the Extent of Axillary Surgery?
Ann Surg Oncol. 2024 Jan 25. doi: 10.1245/s10434-024-14914.
- HIGGINS T, Kantor O, Harrison B, Giordano J, et al
ASO Visual Abstract: Defining the Biology of Estrogen Receptor-Low Positive
Breast Cancer.
Ann Surg Oncol. 2024 Jan 24. doi: 10.1245/s10434-024-14921.
- LAWS A, Leonard S, Hershey E, Stokes S, et al
Upgrade Rates and Breast Cancer Development Among Germline Pathogenic Variant
Carriers with High-Risk Breast Lesions.
Ann Surg Oncol. 2024 Jan 23. doi: 10.1245/s10434-024-14947.
- KOBZEVA-HERZOG A, O'Shea T, Young S, Kenzik K, et al
ASO Visual Abstract: Breast Cancer Screening and BI-RADS Scoring Trends Before
and During the COVID-19 Pandemic in an Academic Safety-Net Hospital.
Ann Surg Oncol. 2024 Jan 22. doi: 10.1245/s10434-024-14896.
BMC Cancer
- SHAO H, Sun Y, Na Z, Jing H, et al
Diagnostic value of applying preoperative breast ultrasound and clinicopathologic
features to predict axillary lymph node burden in early invasive breast cancer: a
study of 1247 patients.
BMC Cancer. 2024;24:112.
- LEE YH, Huang CY, Hsieh YH, Yang CH, et al
A novel computer-assisted tool for 3D imaging of programmed death-ligand 1
expression in immunofluorescence-stained and optically cleared breast cancer
specimens.
BMC Cancer. 2024;24:121.
- YANG ZJ, Xin F, Chen ZJ, Yu Y, et al
Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2
positive breast cancer.
BMC Cancer. 2024;24:134.
BMJ
- MANNU GS, Wang Z, Dodwell D, Broggio J, et al
Invasive breast cancer and breast cancer death after non-screen detected ductal
carcinoma in situ from 1990 to 2018 in England: population based cohort study.
BMJ. 2024;384:e075498.
- SCHMIDT MK, Lips EH, Schmitz RS, Verschuur E, et al
Invasive breast cancer and breast cancer death after non-screen detected ductal
carcinoma in situ.
BMJ. 2024;384:q22.
Br J Cancer
- MATHIEU E, Noguchi N, Li T, Barratt AL, et al
Health benefits and harms of mammography screening in older women (75+ years)-a
systematic review.
Br J Cancer. 2024;130:275-296.
Breast Cancer
- HOSHI N, Uemura T, Tachibana K, Abe S, et al
Endosomal protein expression of gamma1-adaptin is associated with tumor growth
activity and relapse-free survival in breast cancer.
Breast Cancer. 2024 Jan 24. doi: 10.1007/s12282-023-01539.
Breast Cancer (Dove Med Press)
- CHEN CC, Tang WH, Wu CC, Lee TL, et al
Pretreatment Circulating Albumin, Platelet, and RDW-SD Associated with Worse
Disease-Free Survival in Patients with Breast Cancer.
Breast Cancer (Dove Med Press). 2024;16:23-39.
Breast Cancer Res
- NABILA S, Choi JY, Abe SK, Islam MR, et al
Differential patterns of reproductive and lifestyle risk factors for breast
cancer according to birth cohorts among women in China, Japan and Korea.
Breast Cancer Res. 2024;26:15.
- KANG E, Jung JJ, Lim C, Kim HK, et al
Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk
Korean breast cancer patients: a retrospective cohort study.
Breast Cancer Res. 2024;26:14.
- SUN X, Reiner AS, Tran AP, Watt GP, et al
A genome-wide association study of contralateral breast cancer in the Women's
Environmental Cancer and Radiation Epidemiology Study.
Breast Cancer Res. 2024;26:16.
Breast Cancer Res Treat
- COOMBES C, Angelou C, Al-Khalili Z, Hart W, et al
Performance of a novel spectroscopy-based tool for adjuvant therapy
decision-making in hormone receptor-positive breast cancer: a validation study.
Breast Cancer Res Treat. 2024 Jan 20. doi: 10.1007/s10549-023-07229.
- SCHWARTZ CJ, Khorsandi N, Blanco A, Mukhtar RA, et al
Clinicopathologic and genetic analysis of invasive breast carcinomas in women
with germline CHEK2 variants.
Breast Cancer Res Treat. 2024;204:171-179.
- ADDAE JK, Sweeting RS, Meszoely IM, McCaffrey RL, et al
Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal
carcinoma in situ undergoing mastectomy: single-institution experience.
Breast Cancer Res Treat. 2024;204:117-121.
- YANUS GA, Sokolenko AP, Imyanitov EN
Northern origin of the BRCA2 c.5286 T > G founder allele.
Breast Cancer Res Treat. 2024;204:191.
- KESKE A, Weisman P, Ospina-Romero M, Raut P, et al
Breast cancers in monoallelic MUTYH germline mutation carriers have
clinicopathological features overlapping with those in BRCA1 germline mutation
carriers.
Breast Cancer Res Treat. 2024;204:151-158.
- MOKBEL K, Alamoodi M
"Enhancing survival outcomes through breast-conserving therapy in ipsilateral
breast tumor recurrence: insights into metastasis and treatment strategies".
Breast Cancer Res Treat. 2024;204:187.
- KARAKAWA R, Konishi T, Yoshimatsu H, Hashimoto Y, et al
Association between body mass index and outcomes after autologous breast
reconstruction: a nationwide inpatient database study in Japan.
Breast Cancer Res Treat. 2024;204:69-78.
- YEH C, Zhou M, Bapodra N, Hershman D, et al
Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and
offers alternatives for novel assessment of clinical trials.
Breast Cancer Res Treat. 2024;204:39-47.
- AL MASRY Z, Pic R, Dombry C, Devalland C, et al
A new methodology to predict the oncotype scores based on clinico-pathological
data with similar tumor profiles.
Breast Cancer Res Treat. 2024;203:587-598.
- ZHAO YY, Ge HJ, Yang WT, Shao ZM, et al
Secretory breast carcinoma: clinicopathological features and prognosis of 52
patients.
Breast Cancer Res Treat. 2024;203:543-551.
- LEE CS, Goldman L, Grimm LJ, Liu IX, et al
Screening mammographic performance by race and age in the National Mammography
Database: 29,479,665 screening mammograms from 13,181,241 women.
Breast Cancer Res Treat. 2024;203:599-612.
- OPPONG BA, Rumano RP, Paskett ED
Expanding the use of patient navigation: health coaching-based navigation as a
novel approach to addressing deficits in breast cancer survivorship support.
Breast Cancer Res Treat. 2024 Jan 25. doi: 10.1007/s10549-023-07213.
- CETIN K, Kokten S, Sarikamis B, Yildirim S, et al
The association of PD-L1 expression and CD8-positive T cell infiltration rate
with the pathological complete response after neoadjuvant treatment in
HER2-positive breast cancer.
Breast Cancer Res Treat. 2024 Jan 25. doi: 10.1007/s10549-023-07242.
- LICATA L, De Sanctis R, Vingiani A, Cosentini D, et al
Real-world use of multigene signatures in early breast cancer: differences to
clinical trials.
Breast Cancer Res Treat. 2024 Jan 24. doi: 10.1007/s10549-023-07227.
- VAN DE LOO ME, Andour L, van Heesewijk AE, Oosterkamp HM, et al
Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does
it result in more breast-conserving surgery?
Breast Cancer Res Treat. 2024 Jan 24. doi: 10.1007/s10549-023-07222.
- NASRAZADANI A, Marti JLG, Lathrop K, Restrepo A, et al
Poziotinib treatment in patients with HER2-positive advanced breast cancer who
have received prior anti-HER2 regimens.
Breast Cancer Res Treat. 2024 Jan 23. doi: 10.1007/s10549-023-07236.
Cancer
- PRINSLOO S, Kaptchuk TJ, De Ridder D, Lyle R, et al
Brain-computer interface relieves chronic chemotherapy-induced peripheral
neuropathy: A randomized, double-blind, placebo-controlled trial.
Cancer. 2024;130:300-311.
- QU F, Lu R, Liu Q, Wu X, et al
Antibody-drug conjugates transform the outcome of individuals with
low-HER2-expression advanced breast cancer.
Cancer. 2024 Jan 25. doi: 10.1002/cncr.35205.
- XIONG W, Xu T, Liu X, Zhang L, et al
Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated
metastatic breast cancer patients.
Cancer. 2024 Jan 25. doi: 10.1002/cncr.35206.
Cancer Epidemiol Biomarkers Prev
- ZELDIN J, Sandler DP, Ogunsina K, O'Brien KM, et al
Association of fibroids, endometriosis, and gynecologic surgeries with breast
cancer incidence and hormone receptor subtypes.
Cancer Epidemiol Biomarkers Prev. 2024.
Cancer Lett
- JIA F, Sun S, Li J, Wang W, et al
Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive
breast cancer revealed by single-cell RNA sequencing.
Cancer Lett. 2024 Jan 22:216656. doi: 10.1016/j.canlet.2024.216656.
Clin Breast Cancer
- ROLLIN FG, Lee-Rey S, Wong-Serrano E, Habert S, et al
The Importance of Naming Structural Racism as a Root Cause of Racial Inequities
in Breast Cancer Outcomes.
Clin Breast Cancer. 2024 Jan 14:S1526-8209(24)00007.
Eur J Cancer
- GIORGI ROSSI P, Mancuso P, Pattacini P, Campari C, et al
Comparing accuracy of tomosynthesis plus digital mammography or synthetic 2D
mammography in breast cancer screening: baseline results of the MAITA RCT
consortium.
Eur J Cancer. 2024;199:113553.
- TOLANEY SM, Guarneri V, Seo JH, Cruz J, et al
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine
therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early
breast cancer.
Eur J Cancer. 2024;199:113555.
Eur J Surg Oncol
- CAVALCANTE FP, Zerwes FP, Souza ABA, Ziegelmann PK, et al
The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant
chemotherapy in patients with initially node-positive breast cancer.
Eur J Surg Oncol. 2024;50:107967.
Eur Radiol
- DENG Y, Lu Y, Li X, Zhu Y, et al
Prediction of human epidermal growth factor receptor 2 (HER2) status in breast
cancer by mammographic radiomics features and clinical characteristics: a
multicenter study.
Eur Radiol. 2024 Jan 26. doi: 10.1007/s00330-024-10607.
- STEYEROVA P, Kaidar-Person O, Pinker K, Dubsky P, et al
Breast cancer: evaluating the axilla before, during, and after therapy-new
challenges.
Eur Radiol. 2024 Jan 26. doi: 10.1007/s00330-024-10621.
Gene
- KONG L, Jin X
Dysregulation of deubiquitination in breast cancer.
Gene. 2024 Jan 17:148175. doi: 10.1016/j.gene.2024.148175.
Int J Cancer
- SCHMIDT ME, Maurer T, Behrens S, Seibold P, et al
Cancer-related fatigue: Towards a more targeted approach based on classification
by biomarkers and psychological factors.
Int J Cancer. 2024;154:1011-1018.
J Clin Oncol
-
Erratum: Development and Validation of a Genomic Profile for the Omission of
Local Adjuvant Radiation in Breast Cancer.
J Clin Oncol. 2024 Jan 22:JCO2400028. doi: 10.1200/JCO.24.00028.
- SLAMON DJ, Dieras V, Rugo HS, Harbeck N, et al
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
J Clin Oncol. 2024 Jan 22:JCO2300137. doi: 10.1200/JCO.23.00137.
J Nucl Med
- YEH R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, et al
First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in
Patients with HER2-Positive Breast Cancer.
J Nucl Med. 2024 Jan 25:jnumed.123.266392. doi: 10.2967/jnumed.123.266392.
J Surg Oncol
- SARKAR P, Huffman KN, Williams T, Deol A, et al
Rates of breast reconstruction uptake and attitudes toward breast cancer and
survivorship among south asians: A literature review.
J Surg Oncol. 2024 Jan 21. doi: 10.1002/jso.27584.
Lancet
- BRAUNSTEIN LZ
Optimising adjuvant breast radiotherapy via preoperative imaging.
Lancet. 2023 Dec 5:S0140-6736(23)02698-3. doi: 10.1016/S0140-6736(23)02698.
Mod Pathol
- SIQUEIRA JM, Mitani Y, Hoff CO, Bonini F, et al
Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid
Cystic Carcinoma-Specific Prognostic Relevance.
Mod Pathol. 2024;37:100371.
Nature
- CHO MG, Kumar RJ, Lin CC, Boyer JA, et al
MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis.
Nature. 2024;625:585-592.
NPJ Breast Cancer
- JANSSEN LM, Janse MHA, Penning de Vries BBL, van der Velden BHM, et al
Predicting response to neoadjuvant chemotherapy with liquid biopsies and
multiparametric MRI in patients with breast cancer.
NPJ Breast Cancer. 2024;10:10.
- HOOK C, Chatterjee U, Sheng H, Zhu Q, et al
A polygenic score associated with fracture risk in breast cancer patients treated
with aromatase inhibitors.
NPJ Breast Cancer. 2024;10:9.
- MCCANN KE, Goldfarb SB, Traina TA, Regan MM, et al
Selection of appropriate biomarkers to monitor effectiveness of ovarian function
suppression in pre-menopausal patients with ER+ breast cancer.
NPJ Breast Cancer. 2024;10:8.
Oncol Rep
- YU H, Bian Q, Wang X, Wang X, et al
Bone marrow stromal cell antigen 2: Tumor biology, signaling pathway and
therapeutic targeting (Review).
Oncol Rep. 2024;51:45.
- LEI S, Li S, Xiao W, Jiang Q, et al
[Corrigendum] Azurocidin 1 inhibits the aberrant proliferation of triple?negative
breast cancer through the regulation of pyroptosis.
Oncol Rep. 2024;51:49.
PLoS Comput Biol
- ZOU J, Shah O, Chiu YC, Ma T, et al
Systems approach for congruence and selection of cancer models towards precision
medicine.
PLoS Comput Biol. 2024;20:e1011754.
PLoS One
- MIGOWSKI A, Nadanovsky P, Manso de Mello Vianna C
Harms and benefits of mammographic screening for breast cancer in Brazil.
PLoS One. 2024;19:e0297048.
- SHAHMIRZALOU P, Rasekhi A, Jafari Khaledi M, Khayamzadeh M, et al
Comparison performance of the Bayesian Approach with the Weibull and
Birnbaum-Saunders distributions in imputation of time-to-event censors.
PLoS One. 2024;19:e0295977.
- ZARIF S, Abdulkader H, Elaraby I, Alharbi A, et al
Using hybrid pre-trained models for breast cancer detection.
PLoS One. 2024;19:e0296912.
Proc Natl Acad Sci U S A
- BAGHDASARYAN A, Liu H, Ren F, Hsu R, et al
Intratumor injected gold molecular clusters for NIR-II imaging and cancer
therapy.
Proc Natl Acad Sci U S A. 2024;121:e2318265121.
- WANG Y, Xu Z, Wu KL, Yu L, et al
Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer
bone metastasis.
Proc Natl Acad Sci U S A. 2024;121:e2312929121.
Radiology
- ZHOU W, Rahbar H
Quantitative Breast Parenchymal Enhancement to Predict Breast Cancer Recurrence.
Radiology. 2024;310:e240021.
- AREFAN D, Zuley ML, Berg WA, Yang L, et al
Assessment of Background Parenchymal Enhancement at Dynamic Contrast-enhanced MRI
in Predicting Breast Cancer Recurrence Risk.
Radiology. 2024;310:e230269.
Semin Oncol
- WEKKING D, Lambertini M, Dessi M, Denaro N, et al
CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity
and safety.
Semin Oncol. 2024 Jan 13:S0093-7754(24)00002.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016